Andrei Metelitsa, Kaitlyn M Enright, Frank Rosengaus, Luiz Avelar, Stephanie Lam, Philippe Berros, Carlo Di Gregorio, Sabrina Fabi, Firas Hamdan, Steven Liew, Kuldeep Minocha, Rungsima Wanitphakdeedecha, Steven Weiner, Andreas Nikolis
BACKGROUND: The Restylane portfolio of soft tissue fillers spans a wide range of indications, due in part to their complementary manufacturing technologies [non-animal stabilized hyaluronic acid (NASHA) and Optimal Balance Technology (OBT/XpresHAn)]. Using an array of products, injectors can achieve a holistic, natural looking effect for their patients. However, with a wide range of products it may be difficult to choose an optimal combination. AIM: Simplify and align global use recommendations for NASHA versus OBT products...
February 6, 2024: Journal of Cosmetic Dermatology